Supplementary Table S1. Baseline clinicopathological features of patients treated with sonidegib predicting clinical remission.

	Clinical remission		
	Yes (*n*=8)	**No (*n*=5)**	***p value***
Female (%)	62.5	20.0	0.27*
Age (median (IQR))	58.5 (27)	55.0 (11)	0.83+
Age of symptoms onset: **median (IQR)** **≤ 20 years (%)**	 15.5 (7) 87.5	 28.0 (16) 40.0	 0.065+ 0.22*
Age of BCC onset: **median (IQR)** **≤20 years (%)**	 25.0 (17.7) 37.5	 28.5 (8.2) 0.0	 0.68+ 0.23*
Great number of BCC not justified by photo exposition or phenotype (%)	100.0	80.0	0.38*
Number of BCC ≥100 (%) **	0.0	60.0	***0.03****
Number of BCC/year ≥4 (%) **	0.0	100.0	***0.01****
FH BCC (%)	87.5	60.0	0.51*
Presence of comorbidity (%)	50.0	20.0	0.56*
Pits (%)	62.5	80.0	1.0*
Age of Pits onset (median (IQR))	30.0 (24.5)	43.0 (42.5)	0.56+
Presence of keratocysts (%)	100.0	60.0	0.13*
Presence of bilamellar calcification (%)	25.0	40.0	1.0*
Presence of rib abnormalities (%)	12.5	0.0	1.0*
Presence of macrocephaly (%)	62.5	60.0	1.0*
Presence of labiopalatoschisis (%)	0.0	40.0	0.15*
Presence of ovarian fibroids (%)	25.0	20.0	1.0*
Presence of eye problems (%)	25.0	0.0	0.48*
Presence of recurrent BCC (%)	62.5	100.0	0.23*
Number of recurrences (median (IQR))	1.0 (2.75)	3.0 (3)	0.09+
Number of recurrences in high-risk areas (median (IQR))	0.5 (1.0)	3.0 (3.5)	***0.04***+

Number of BCC with local invasion (median (IQR)	1.0 (1.5)	1.5 (1.75)	0.68+

*p-value derived from Fisher's exact test; +p-value obtained by Mann Whitney test.


** BCC diagnosed prior to sonidegib introduction

Abbreviation: IQR, Interquartile range; BCC, basal cell carcinoma; FH, family history.

Photo S1. Clinical and hystological presentation of laBCC before Sonidegib treatment. **1B** Clinical and histological remission after three months of Sonidegib.

A.





B.



